



ESSEX BIO-TECHNOLOGY LIMITED
億勝生物科技有限公司

(Stock Code: 1061)

Essex Bio-Technology Included by MSCI
as A Constituent of The MSCI China Small Cap Index

Hong Kong, 15 May 2019 -- Essex Bio-Technology Limited (“EssexBio” or the “Group” or the Company, Stock code: 1061) is pleased to announce that the Company has been included by Morgan Stanley Capital International (“MSCI”) as a constituent of the MSCI China Small Cap Index, which will be effective as of the close of 28 May 2019.

MSCI is a leading provider of global equity indexes and benchmark related products and services to investors worldwide. The MSCI China Small Cap Index is designed to measure the performance of the small cap segment of the China market. Constituent stocks included in the index are generally companies with operating base in China, demonstrating excellent performance and development prospect.

The Board of Directors believe that the inclusion of the Company into above global index proved the worldwide recognition of the Company’s track record in capital market. As MSCI is one of the most widely-used international equity benchmark by global institutional investors, more engagement by international funds is expected and should further contribute to the liquidity and market value of the Company, enhancing its corporate image and accelerating the future development of its business in the biopharmaceutical industry.

About EssexBio

Essex Bio-Technology Limited is a bio-pharmaceutical company, started in early 90’s, a pioneer in bio-pharmaceutical industry in China, that develops, manufactures and commercialises genetically engineered

therapeutic rb-bFGF, a basic fibroblast growth factor, with established mechanism of action in cellular proliferation, differentiation and migration.

The Company currently has five commercialised bio-pharmaceutical products, formulated with rb-bFGF, in China, out of which 3 are approved by CFDA (now the National Medical Products Administration (“NMPA”)) as Category I drugs. The products are being marketed & sold as Beifushu, Beifuji & Beifuxin, for treatment of ocular surface wounds and topical (skin) surface wounds respectively. Beifuji is the first in the world to have obtained approval from NMPA for commercialization in 1998.

In addition, the Group has three NMPA approved preservative-free, single-dose eye drops: Tobramycin, Levofloxacin and Sodium Hyaluronate.

The Company focuses on two main therapeutics: Ophthalmology and Surgical arena of topical (skin) surface wounds, which primarily covers Dermatology, Stomatology and Obstetrics & Gynaecology, while selectively pursuing therapeutics in Neurology, Oncology and Orthopaedics. The Company maintains a pipeline of multi-project in R&D and on various stages of clinical programs, of which several projects involving growth factors and antibody and a handful of projects are on unit dose for Ophthalmic and Respiratory disease.

The Company’s products and its 3rd party products are marketed and sold through more than 6,300 hospitals in China and are managed directly by its 42 regional sales offices with about 1,320 sales and marketing people. Its 3rd party products, notably are inclusive of Xalacom eye drops and Xalatan eye drops of Pfizer (for Ophthalmology), Iodized Lecithin Capsules (for Ophthalmology), Yi Xue An Granules (for Obstetrics & Gynaecology).

Zhixin Investor Relations Consultant issued this press release on behalf of **Essex Bio-Technology Limited**.

For further information, please contact:

Zhixin Investor Relations Consultant Limited

Ms. Lin Xiaoyan

Tel: +86 (755) 8323 9767

E-mail: Linxiaoyan@zhixincaijing.com